NeuroMolecular Medicine

, Volume 10, Issue 3, pp 169–178 | Cite as

Perturbed Autonomic Nervous System Function in Metabolic Syndrome

  • Nicholas Tentolouris
  • Georgia Argyrakopoulou
  • Nicholas Katsilambros
Original Paper
First Online:
Received:
Accepted:

Abstract

The metabolic syndrome is characterized by the clustering of various common metabolic abnormalities in an individual and it is associated with increased risk for the development of type 2 diabetes and cardiovascular diseases. Its prevalence in the general population is approximately 25%. Central fat accumulation and insulin resistance are considered as the common denominators of the abnormalities of the metabolic syndrome. Subjects with metabolic syndrome have autonomic nervous system dysfunction characterized by predominance of the sympathetic nervous system in many organs, i.e. heart, kidneys, vasculature, adipose tissue, and muscles. Sympathetic nervous system activation in metabolic syndrome is detected as increased heart rate and blood pressure, diminished heart rate variability, baroreceptor dysfunction, enhanced lipolysis in visceral fat, increased muscle sympathetic nerve activity, and high urine or plasma catecholamine concentrations as well as turnover rates. The augmented sympathetic activity in individuals with metabolic syndrome worsens prognosis of this high-risk population. The mechanisms linking metabolic syndrome with sympathetic activation are complex and not clearly understood. Whether sympathetic overactivity is involved in the development of the metabolic syndrome or is a consequence of it remains to be elucidated since data from prospective studies are missing. Intervention studies have demonstrated that the autonomic disturbances of the metabolic syndrome may be reversible.

Keywords

Sympathetic nervous system Metabolic syndrome Obesity Hypertension Dyslipidemia Diabetes mellitus Heart rate variability Baroreceptor Catecholamines 
This is a preview of subscription content, log in to check access.

References

  1. Aldo Ferrara, L., Guida, L., Ferrara, F., et al. (2007). Blood pressure at rest, during 24 h monitoring and in response to sympathetic stimulation in hypertensive patients with metabolic syndrome. International Journal of Cardiology, 117, 312–316.PubMedCrossRefGoogle Scholar
  2. Alvarez, G. E., Beske, S. D., Ballard, T. P., & Davy, K. P. (2002). Sympathetic neural activation in visceral obesity. Circulation, 106, 2533–2536.PubMedCrossRefGoogle Scholar
  3. Anderson, E. A., Hoffman, R. P., Balon, T. W., Sinkey, C. A., & Mark, A. L. (1991). Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. Journal of Clinical Investigation 87, 2246–2252.PubMedCrossRefGoogle Scholar
  4. Aso, Y., Wakabayashi, S., Nakano, T., Yamamoto, R., Takebayashi, K., & Inukai, T. (2006). High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 55, 1014–1021.PubMedCrossRefGoogle Scholar
  5. Assmann, G., Guerra, R., Fox, G., et al. (2007). Harmonizing the definition of the metabolic syndrome: Comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. American Journal of Cardiology 99, 541–548.PubMedCrossRefGoogle Scholar
  6. Bernardi, L., Ricordi, L., Lazzari, P., et al. (1992). Impaired circardian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation, 86, 1443–1452.PubMedGoogle Scholar
  7. Berne, C., Fagius, J., & Niklasson, F. (1989). Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. Journal of Clinical Investigation, 84, 1403–1409.PubMedCrossRefGoogle Scholar
  8. Berne, C., Fagius, J., Pollare, T., & Hjemdahl, P. (1992). The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia, 35, 873–879.PubMedCrossRefGoogle Scholar
  9. Beske, S. D., Alvarez, G. E., Ballard, T. P., & Davy, K. P. (2002). Reduced cardiovagal baroreflex gain in visceral obesity: Implications for the metabolic syndrome. American Journal of Physiology-Heart and Circulatory Physiology, 282, H630–635.PubMedGoogle Scholar
  10. Bianchi, C., Penno, G., Malloggi, L., et al. (2008). Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutrition Metabolism and Cardiovascular Diseases, 18, 31–38.CrossRefGoogle Scholar
  11. Boguszewski, M. C., Johannsson, G., Fortes, L. C., & Sverrisdottir, Y. B. (2004). Low birth size and final height predict high sympathetic nerve activity in adulthood. Journal of Hypertension 22, 1157–1163.PubMedCrossRefGoogle Scholar
  12. Boulton, A. J., Vinik, A. I., Arezzo, J. C., et al. (2005). American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28, 956–962.PubMedCrossRefGoogle Scholar
  13. Branth, S., Ronquist, G., Stridsberg, M., et al. (2007). Development of abdominal fat and incipient metabolic syndrome in young healthy men exposed to long-term stress. Nutrition Metabolism and Cardiovascular Diseases, 17, 427–435.CrossRefGoogle Scholar
  14. Brunner, E. J., Hemingway, H., Walker, B. R., et al. (2002). Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 106, 2659–2665.PubMedCrossRefGoogle Scholar
  15. Busetto, L., Digito, M., Dalla Monta, P., Carraro, R., & Enzi, G. (1993). Omental and epigastric adipose tissue lipolytic activity in human obesity. Effect of abdominal fat distribution and relationship with hyperinsulinemia. Hormone and Metabolic Research, 25, 365–371.PubMedGoogle Scholar
  16. Chaiken, R. L., & Banerji, M. A. (2006). Metabolic syndrome. In C. S. Mantzoros (Ed.), Obesity and diabetes (pp. 155–168). Totowa, NJ: Humana.Google Scholar
  17. Chan, J. L., Mietus, J. E., Raciti, P. M., Goldberger, A. L., & Mantzoros, C. S. (2007). Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clinical Endocrinology (Oxford), 66, 49–57.Google Scholar
  18. Chew, G. T., Gan, S. K., & Watts, G. F. (2006). Revisiting the metabolic syndrome. Medical Journal of Australia 185, 445–449.PubMedGoogle Scholar
  19. Correia, M. L., & Rahmouni, K. (2006). Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obesity & Metabolism, 8, 603–610.CrossRefGoogle Scholar
  20. Dalla Pozza, R. D., Bechtold, S., Putzker, S., Bonfig, W., Netz, H., & Schwarz, H. P. (2006). Young adults born small for gestational age: Is reduced baroreceptor sensitivity a risk factor for hypertension? Clinical Cardiology, 29, 215–218.PubMedCrossRefGoogle Scholar
  21. Day, C. (2007). Metabolic syndrome, or What you will: Definitions and epidemiology. Diabetics & Vascular Disease Research, 4, 32–38.CrossRefGoogle Scholar
  22. DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979). Glucose clamp technique: A method for quantifying insulin secretion and resistance. American Journal of Physiology, 237, E214–223.PubMedGoogle Scholar
  23. Ducimetiere, P., Eschwege, E., Papoz, L., Richard, J. L., Claude, J. R., & Rosselin, G. (1980). Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia, 19, 205–210.PubMedCrossRefGoogle Scholar
  24. Emdin, M., Gastaldelli, A., Muscelli, E., et al. (2001). Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss. Circulation, 103, 513–519.PubMedGoogle Scholar
  25. Esler, M., Ferrier, C., Lambert, G., Eisenhofer, G., Cox, H., & Jennings, G. (1991). Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension, 17(Suppl), III29–III35.PubMedGoogle Scholar
  26. Fehm, H. L., Kern, W., & Peters, A. (2006). The selfish brain: Competition for energy resources. Progress in Brain Research, 153, 129–140.PubMedCrossRefGoogle Scholar
  27. Ferraro, S., Fazio, S., Santomauro, M., et al. (1990). Cardiac function and sympathetic activity in young diabetics. Diabetes Research and Clinical Practice, 8, 91–99.PubMedCrossRefGoogle Scholar
  28. Frontoni, S., Bracaglia, D., & Gigli, F. (2005). Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutrition Metabolism and Cardiovascular Diseases, 15, 441–449.CrossRefGoogle Scholar
  29. Fulop, T., Tessier, D., & Carpentier, A. (2006). The metabolic syndrome. Pathologie Biologie (Paris) 54, 375–386.CrossRefGoogle Scholar
  30. Gadegbeku, C. A., Dhandayuthapani, A., Sadler, Z. E., & Egan, B. M. (2002). Raising lipids acutely reduces baroreflex sensitivity. American Journal of Hypertension, 15, 479–485.PubMedCrossRefGoogle Scholar
  31. Galletti, F., Barbato, A., Versiero, M., et al. (2007). Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: An 8-year follow-up study. Journal of Hypertension, 25, 1671–1677.PubMedCrossRefGoogle Scholar
  32. Grassi, G. (1998). Role of the sympathetic nervous system in human hypertension. Journal of Hypertension, 16, 1979–1987.PubMedCrossRefGoogle Scholar
  33. Grassi, G. (2006). Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertension Research, 29, 839–847.PubMedCrossRefGoogle Scholar
  34. Grassi, G., Dell’Oro, R., Facchini, A., Quarti Trevano, F., Bolla, G. B., & Mancia, G. (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension, 22, 2363–2369.PubMedCrossRefGoogle Scholar
  35. Grassi, G., Dell’Oro, R., Quarti-Trevano, F., et al. (2005). Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia, 48, 1359–1365.PubMedCrossRefGoogle Scholar
  36. Grassi, G., Quarti-Trevano, F., Seravalle, G., & Dell’oro, R. (2007). Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutrition Metabolism and Cardiovascular Diseases, 17, 473–481.CrossRefGoogle Scholar
  37. Grassi, G., & Seravalle, G. (2006). Autonomic imbalance and metabolic syndrome: Unravelling interactions, mechanisms and outcomes. Journal of Hypertension, 24, 47–49.PubMedCrossRefGoogle Scholar
  38. Grassi, G., Seravalle, G., Bertinieri, G., et al. (2000). Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. Journal of Hypertension, 18, 587–593.PubMedCrossRefGoogle Scholar
  39. Hayes, L., Pearce, M. S., & Unwin, N. C. (2006). Lifecourse predictors of normal metabolic parameters in overweight and obese adults. International Journal of Obesity (London), 30, 970–976.CrossRefGoogle Scholar
  40. Haynes, W. G. (2000). Interaction between leptin and sympathetic nervous system in hypertension. Current Hypertension Reports, 2, 311–318.PubMedCrossRefGoogle Scholar
  41. Hoffstedt, J., Wahrenberg, H., Thorne, A., & Lonnqvist, F. (1996). The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39, 838–844.PubMedCrossRefGoogle Scholar
  42. Holl, R. W., Pavlovic, M., Heinze, E., & Thon, A. (1999). Circadian blood pressure during the early course of type 1 diabetes. Analysis of 1,011 ambulatory blood pressure recordings in 354 adolescents and young adults. Diabetes Care, 22, 1151–1157.PubMedCrossRefGoogle Scholar
  43. Howard, G., O’Leary, D. H., Zaccaro, D., et al. (1996). Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation, 93, 1809–1817.PubMedGoogle Scholar
  44. Huggett, R. J., Burns, J., Mackintosh, A. F., & Mary, D. A. (2004). Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension, 44, 847–852.PubMedCrossRefGoogle Scholar
  45. Ikeda, T., Matsubara, T., Sato, Y., & Sakamoto, N. (1993). Circadian blood pressure variation in diabetic patients with autonomic neuropathy. Journal of Hypertension, 11, 581–587.PubMedCrossRefGoogle Scholar
  46. Iribarren, C., Go, A. S., Husson, G., et al. (2006). Metabolic syndrome and early-onset coronary artery disease: Is the whole greater than its parts? Journal of the American College of Cardiology, 48, 1800–1807.PubMedCrossRefGoogle Scholar
  47. Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005). The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 28, 2289–2304.PubMedCrossRefGoogle Scholar
  48. Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. Journal of Clinical Investigation, 106, 473–481.PubMedCrossRefGoogle Scholar
  49. Ko, G. T., Cockram, C. S., Chow, C. C., et al. (2006). Metabolic syndrome by the international diabetes federation definition in Hong Kong Chinese. Diabetes Research and Clinical Practice, 73, 58–64.PubMedCrossRefGoogle Scholar
  50. Kreier, F., Yilmaz, A., Kalsbeek, A., et al. (2003). Hypothesis: Shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes, 52, 2652–2656.PubMedCrossRefGoogle Scholar
  51. Lembo, G., Napoli, R., Capaldo, B., et al. (1992). Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. Journal of Clinical Investigation, 90, 24–29.PubMedCrossRefGoogle Scholar
  52. Lembo, G., Rendina, V., Iaccarino, G., Lamenza, F., Volpe, M., & Trimarco, B. (1993). Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. Hypertension, 21, 1015–1019.PubMedGoogle Scholar
  53. Liao, D., Sloan, R. P., Cascio, W. E., et al. (1998). Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care, 21, 2116–2122.PubMedCrossRefGoogle Scholar
  54. Liatis, S., Tentolouris, N., & Katsilambros, N. (2004). Cardiac autonomic nervous system activity in obesity. Pediatric Endocrinology Review, 1(Suppl 3), 476–483.Google Scholar
  55. Lindgren, K., Hagelin, E., Hansen, N., & Lind, L. (2006). Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. Journal of Hypertension, 24, 143–150.PubMedCrossRefGoogle Scholar
  56. Lopes, H. F., Silva, H. B., Consolim-Colombo, F. M., et al. (2000). Autonomic abnormalities demonstrable in young normotensive subjects who are children of hypertensive parents. Brazilian Journal of Medical and Biological Research, 33, 51–54.PubMedCrossRefGoogle Scholar
  57. Lopes, H. F., Stojiljkovic, M. P., Zhang, D., Goodfriend, T. L., & Egan, B. M. (2001). The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. American Journal of Hypertension, 14, 1032–1037.PubMedCrossRefGoogle Scholar
  58. Lu, B., Yang, Y., Song, X., et al. (2006). An evaluation of the International Diabetes Federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus. Metabolism, 55, 1088–1096.PubMedCrossRefGoogle Scholar
  59. Maison, P., Byrne, C. D., Hales, C. N., Day, N. E., & Wareham, N. J. (2001). Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care, 24, 1758–1763.PubMedCrossRefGoogle Scholar
  60. Mancia, G., Bousquet, P., Elghozi, J. L., et al. (2007a). The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension, 25, 909–920.PubMedGoogle Scholar
  61. Mancia, G., Bombelli, M., Corrao, G., et al. (2007b). Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: Daily life blood pressure, cardiac damage, and prognosis. Hypertension, 49, 40–47.PubMedCrossRefGoogle Scholar
  62. McNeill, A. M., Rosamond, W. D., Girman, C. J., et al. (2005). The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care, 28, 385–390.PubMedCrossRefGoogle Scholar
  63. Meigs, J. B., Wilson, P. W., Nathan, D. M., D’Agostino, R. B., Sr., Williams, K., & Haffner, S. M. (2003). Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 52, 2160–2167.PubMedCrossRefGoogle Scholar
  64. Monami, M., Marchionni, N., & Masotti, G., Mannucci, E. (2007). IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obesity & Metabolism, 9, 350–353.CrossRefGoogle Scholar
  65. Modan, M., & Halkin, H. (1991). Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care, 14, 470–487.PubMedCrossRefGoogle Scholar
  66. Morgan, D. A., Balon, T. W., Ginsberg, B. H., & Mark, A. L. (1993). Nonuniform regional sympathetic nerve responses to hyperinsulinemia in rats. American Journal of Physiology, 264, R423–427.PubMedGoogle Scholar
  67. Muntzel, M. S., Morgan, D. A., Mark, A. L., & Johnson, A. K. (1994). Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. American Journal of Physiology, 267, R1350–R1355.PubMedGoogle Scholar
  68. Nonogaki, K. (2000). New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia, 43, 533–549.PubMedCrossRefGoogle Scholar
  69. O’Hare, J. A., Minaker, K. L., Meneilly, G. S., Rowe, J. W., Pallotta, J. A., & Young, J. B. (1989). Effect of insulin on plasma norepinephrine and 3,4-dihydroxyphenylalanine in obese men. Metabolism, 38, 322–329.PubMedCrossRefGoogle Scholar
  70. Oda, E. (2006). The metabolic syndrome (emperor) wears no clothes: Response to Kahn. Diabetes Care, 29, 2566.PubMedCrossRefGoogle Scholar
  71. Orchard, T. J., Eichner, J., Kuller, L. H., Becker, D. J., McCallum, L. M., & Grandits, G. A. (1994). Insulin as a predictor of coronary heart disease: Interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Annals of Epidemiology, 4, 40–45.PubMedCrossRefGoogle Scholar
  72. Ostman, J., Arner, P., Engfeldt, P., & Kager, L. (1979). Regional differences in the control of lipolysis in human adipose tissue. Metabolism, 28, 1198–1205.PubMedCrossRefGoogle Scholar
  73. Paolisso, G., Manzella, D., Rizzo, M. R., et al. (2000). Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. American Journal of Clinical Nutrition, 72, 723–730.PubMedGoogle Scholar
  74. Perin, P. C., Maule, S., & Quadri, R. (2001). Sympathetic nervous system, diabetes, and hypertension. Clinical and Experimental Hypertension, 23, 45–55.PubMedCrossRefGoogle Scholar
  75. Pikkujamsa, S. M., Huikuri, H. V., Airaksinen, K. E., et al. (1998). Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. American Journal of Hypertension, 11, 523–531.PubMedCrossRefGoogle Scholar
  76. Pyorala, K. (1979). Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care, 2, 131–141.PubMedCrossRefGoogle Scholar
  77. Qiao, Q. (2006). Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia, 49, 2837–2846.PubMedCrossRefGoogle Scholar
  78. Rahmouni, K., & Morgan, D. A. (2007). Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension, 49, 647–652.PubMedCrossRefGoogle Scholar
  79. Rathmann, W., Haastert, B., Icks, A., et al. (2006). Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: The KORA Survey 2000. Diabetes Care, 29, 461.PubMedCrossRefGoogle Scholar
  80. Reaven, G. M. (1993). Role of insulin resistance in human disease (syndrome X): An expanded definition. Annual Review of Medicine, 44, 121–131.PubMedCrossRefGoogle Scholar
  81. Reaven, G. M. (2006). The metabolic syndrome: Is this diagnosis necessary? American Journal of Clinical Nutrition, 83, 1237–1247.PubMedGoogle Scholar
  82. Rowe, J. W., Young, J. B., Minaker, K. L., Stevens, A. L., Pallotta, J., & Landsberg, L. (1981). Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes, 30, 219–225.PubMedGoogle Scholar
  83. Scherrer, U., Randin, D., Tappy, L., Vollenweider, P., Jequier, E., & Nicod, P. (1994). Body fat and sympathetic nerve activity in healthy subjects. Circulation, 89, 2634–2640.PubMedGoogle Scholar
  84. Scherrer, U., & Sartori, C. (1997). Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation, 96, 4104–4113.PubMedGoogle Scholar
  85. Scherrer, U., Vollenweider, P., Randin, D., Jequier, E., Nicod, P., & Tappy, L. (1993). Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation, 88, 388–394.PubMedGoogle Scholar
  86. Skrapari, I., Tentolouris, N., Perrea, D., Bakoyiannis, C., Papazafiropoulou, A., & Katsilambros, N. (2007). Baroreflex sensitivity in obesity: Relationship with cardiac autonomic nervous system activity. Obesity (Silver Spring), 15, 1685–1693.CrossRefGoogle Scholar
  87. Skyler, J. S., Marks, J. B., & Schneiderman, N. (1995). Hypertension in patients with diabetes mellitus. American Journal of Hypertension, 8(12 Pt 2), 100s–105s.PubMedCrossRefGoogle Scholar
  88. Stein, P. K., Barzilay, J. I., Domitrovich, P. P., et al. (2007). The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: The Cardiovascular Health Study. Diabetic Medicine, 24, 855–863.PubMedCrossRefGoogle Scholar
  89. Stern, M. P., Williams, K., Gonzalez-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004). Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care, 27, 2676–2681.PubMedCrossRefGoogle Scholar
  90. Straznicky, N. E., Lambert, E. A., Lambert, G. W., Masuo, K., Esler, M. D., & Nestel, P. J. (2005). Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. The Journal of Clinical Endocrinology and Metabolism, 90, 5998–6005.PubMedCrossRefGoogle Scholar
  91. Straznicky, N. E., Louis, W. J., McGrade, P., & Howes, L. G. (1993). The effects of dietary lipid modification on blood pressure, cardiovascular reactivity and sympathetic activity in man. Journal of Hypertension, 11, 427–437.PubMedCrossRefGoogle Scholar
  92. Sundstrom, J., Vallhagen, E., Riserus, U., et al. (2006). Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care, 29, 1673–1674.PubMedCrossRefGoogle Scholar
  93. Tentolouris, N., Liatis, S., & Katsilambros, N. (2006). Sympathetic system activity in obesity and metabolic syndrome. Annals of the New York Academy of Sciences, 1083, 129–152.PubMedCrossRefGoogle Scholar
  94. Tentolouris, N., Tsigos, C., Perea, D., et al. (2003). Differential effects of high-fat and high-carbohydrate isoenergetic meals on cardiac autonomic nervous system activity in lean and obese women. Metabolism, 52, 1426–1432.PubMedCrossRefGoogle Scholar
  95. Vollenweider, P., Randin, D., Tappy, L., Jequier, E., Nicod, P., & Scherrer, U. (1994). Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. Journal of Clinical Investigation, 93, 2365–2371.PubMedCrossRefGoogle Scholar
  96. Vollenweider, P., Tappy, L., Randin, D., et al. (1993). Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. Journal of Clinical Investigation, 92, 147–154.PubMedCrossRefGoogle Scholar
  97. Wannamethee, S. G., Shaper, A. G., Lennon, L., & Morris, R. W. (2005). Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine, 165, 2644–2650.PubMedCrossRefGoogle Scholar
  98. Wingard, D. L., Barrett-Connor, E. L., & Ferrara, A. (1995). Is insulin really a heart disease risk factor. Diabetes Care, 18, 1299–1304.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Nicholas Tentolouris
    • 1
    • 2
  • Georgia Argyrakopoulou
    • 1
  • Nicholas Katsilambros
    • 1
  1. 1.1st Department of Propaedeutic MedicineAthens University Medical SchoolAthensGreece
  2. 2.AthensGreece

Personalised recommendations